In8bio
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 31
- Market Cap
- -
- Website
- http://www.in8bio.com
- Introduction
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- In8bio Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT05664243
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Louisville Hospital/James Graham Brown Cancer Center, Louisville, Kentucky, United States
News
IN8bio Adds Ohio State University to INB-100 Gamma-Delta T Cell Therapy Trial for Leukemia Patients
IN8bio has expanded its Phase 1 clinical trial of INB-100 by adding The Ohio State University as a new clinical site to accelerate enrollment.
IN8bio's Novel Gamma-Delta T Cell Engager Shows Promise for Autoimmune Disease Treatment
IN8bio presented preclinical data for INB-619, a first-in-class pan-gamma delta T cell engager that achieved complete B cell depletion with efficacy equivalent to FDA-approved compounds blinatumomab and mosunetuzumab.
TC Biopharm Leads Gamma Delta T Cell Therapy Development with Over 25 Clinical Programs Worldwide
TC Biopharm's OmnImmune is advancing through a pivotal Phase 2/3 trial for acute myeloid leukemia, representing one of the most advanced gamma delta T cell therapies globally.
IN8bio's INB-100 Shows Promising Phase 1 Results with Zero Relapses in High-Risk AML Patients
IN8bio's allogeneic gamma-delta T cell therapy INB-100 demonstrated remarkable efficacy with no relapses in AML patients over a median follow-up of 20.1 months.
Gene and Cell Therapies Show Promise in Treating CNS Disorders
The market for gene and cell therapies targeting CNS disorders was valued at approximately USD 1 billion in 2021 and is projected to grow significantly by 2034.
IN8bio Pauses INB-400 Glioblastoma Trial to Focus on AML Program
IN8bio has suspended enrollment in the phase 2 trial of INB-400, a gamma-delta T-cell therapy, for newly diagnosed glioblastoma multiforme in combination with temozolomide.
IN8bio Restructures to Focus on INB-100 AML Program Following $12.4 Million Private Placement
IN8bio is prioritizing its INB-100 program for acute myeloid leukemia (AML) due to promising results and a challenging financing environment.